The ESMO (European Society for Medical Oncology) and NCCN (National Comprehensive Cancer Network) guidelines have provided evidence-based targeted optimizing recommendations for HR+/HER2- BC and HR+/HER2- ABC and descriptions of their clinicopathological features (10, 11). This evidence concerns the gene ERBB2 and breast cancer.